McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Andrew Williams is quoted in an April 7, 2016 online edition of MedPage Today in an article entitled, “A Rocky Start for Biosimilar Inflectra?.” This week, when the FDA approved the biosimilar drug Inflectra as an alternative to infliximab (Remicade), it was only the second biosimilar to be granted approval in the United States, and was the first monoclonal antibody biosimilar. But it may be years before the product reaches U.S. pharmacies. View the article